<DOC>
	<DOCNO>NCT00316550</DOCNO>
	<brief_summary>The purpose study assess effect AV608 , neurokinin 1 ( NK-1 ) antagonist , subject Irritable Bowel Syndrome .</brief_summary>
	<brief_title>Pilot Study Assess Effects AV608 Irritable Bowel Syndrome</brief_title>
	<detailed_description>This single-center , randomize , double-blind , placebo-controlled , cross-over study ass effect AV608 brain processing visceral stimuli emotional visual cue subject IBS . Female subject 18 65 year age meet diagnostic criterion Irritable Bowel Syndrome eligible study . Eligible subject complete baseline fMRI image procedure include emotional visual cue visceral stimulation . All subject participate study receive 3 week treatment AV608 3 week treatment placebo course study ; order two treatment subject randomly determine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Female , 18 65 year age , inclusive Current diagnosis Irritable Bowel Syndrome ( IBS ) Subjects 50 year age old must barium enema flexible sigmoidoscopy colonoscopy provide record test Willing participate study evidence sign , write informed consent form ( ICF ) If female childbearing potential , willing avoid pregnancy practice adequate birth control time study enrollment least 30 day final dose study medication If female , negative pregnancy test result Right hand Ambulatory outpatient Agrees refrain blood donation course study Written oral fluency English language Evidence structural abnormality gastrointestinal tract GI diseases/conditions Current evidence diagnosis peptic ulcer Endoscopic bowel evaluation evidence cancer , inflammatory bowel disease , structural disease History abdominal surgery adhesion lysis gastrointestinal surgery History gastroesophageal reflux disease control stable dose medication Any evidence treatment malignancy within previous 5 year Clinical evidence disease may interfere participation study Existence surgical medical condition interfere absorption , distribution , metabolism excretion study drug Symptoms significant clinical illness within 2 week prior Screening Type 1 diabetes mellitus , insulindependent Type 2 diabetes mellitus , thyroid disorder endocrine disorder well control appropriate therapy A QTc interval great equal 450 msec Screening Presence psychotic disorder , bipolar disorder , alcohol substance dependence ( nicotine dependence ) eat disorder within previous year accord DSMIVTR criterion Seizure disorder Subjects previously participate clinical trial AV608 ( previously know NKP608 CGP608 ) Positive drug test result Screening Use investigational drug , product device within 30 day prior Screening Planned use certain drug study affect central nervous system , gastrointestinal motility , autonomic activity pain sensation Use pimozide , terfenadine , astemizole , cisapride study Presence moderate severe allergy Regular intake 2 unit alcohol per day Pregnant breast feeding Subjects morbid obesity Subjects metal implant large tattoo Any clinically significant abnormality Screening physical examination , ECG laboratory test Members investigative staff immediate family member Any condition investigator believe would jeopardize safety right subject would render subject unable comply study protocol Regular use 10 cigarette per day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Irritable Bowel Syndrome ( IBS )</keyword>
</DOC>